Northern Trust Corp boosted its stake in American Renal Associates Holdings Inc (NYSE:ARA) by 33.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,693 shares of the company’s stock after acquiring an additional 35,965 shares during the period. Northern Trust Corp owned 0.46% of American Renal Associates worth $2,666,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its stake in American Renal Associates by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock valued at $726,000 after buying an additional 285 shares during the period. Rhumbline Advisers raised its position in shares of American Renal Associates by 2.7% during the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock worth $248,000 after purchasing an additional 354 shares during the period. Alliancebernstein L.P. raised its position in American Renal Associates by 3.0% in the 2nd quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after buying an additional 400 shares during the last quarter. Teachers Advisors LLC raised its position in American Renal Associates by 8.8% in the 2nd quarter. Teachers Advisors LLC now owns 17,910 shares of the company’s stock valued at $332,000 after buying an additional 1,444 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in American Renal Associates by 2.9% in the 1st quarter. Geode Capital Management LLC now owns 77,726 shares of the company’s stock valued at $1,312,000 after buying an additional 2,180 shares during the last quarter. Institutional investors and hedge funds own 93.27% of the company’s stock.
Several research analysts have recently weighed in on the company. SunTrust Banks set a $18.00 price target on American Renal Associates and gave the stock a “buy” rating in a research note on Sunday, October 15th. Zacks Investment Research upgraded American Renal Associates from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Thursday, November 16th. Finally, Leerink Swann restated an “outperform” rating and issued a $17.00 target price (down previously from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $17.75.
American Renal Associates Holdings Inc (NYSE:ARA) opened at $14.18 on Wednesday. The firm has a market capitalization of $442.97, a PE ratio of 21.01, a P/E/G ratio of 1.24 and a beta of 4.29. American Renal Associates Holdings Inc has a 1-year low of $9.91 and a 1-year high of $24.82. The company has a current ratio of 1.16, a quick ratio of 1.13 and a debt-to-equity ratio of 3.57.
American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The company had revenue of $187.71 million for the quarter, compared to analyst estimates of $194.60 million. American Renal Associates had a positive return on equity of 15.80% and a negative net margin of 2.15%. The firm’s revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. research analysts anticipate that American Renal Associates Holdings Inc will post 0.57 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/06/american-renal-associates-holdings-inc-ara-shares-bought-by-northern-trust-corp.html.
American Renal Associates Profile
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.